0001703057false00017030572024-08-062024-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2024
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
2215 Yukon Street
Vancouver, BC
V5Y 0A1
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 2.02    Results of Operations and Financial Condition
On August 6, 2024, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01    Regulation FD Disclosure
In connection with its earnings call on August 6, 2024, to discuss its results for the quarter ended June 30, 2024, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.
The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01    Financial Statements and Exhibits
(d)Exhibits
Exhibit
No.		Description
99.1
99.2
104Cover Page Interactive Data File (embedded as Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2024ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

capture.jpg





NEWS RELEASE


AbCellera Reports Q2 2024 Business Results

08/06/2024


VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“This quarter, we made important progress on our internal pipeline and aim to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025. In parallel, we have focused preclinical work on our T-cell engager platform to four molecules for indications in oncology and autoimmunity,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Since our last earnings release, two of our partners have achieved notable milestones, including Abdera's IND clearance and Fast Track designation for ABD-147 and Invetx's upcoming acquisition by a global leader in animal health. AbCellera is a founding partner of both Abdera and Invetx. In addition, we have recently announced an expansion of our partnership with Lilly.”

Q2 2024 Business Summary
●ABCL635 and ABCL575 remain on track for anticipated Clinical Trial Applications (CTAs) in the second quarter of 2025.
●Disclosed three T-cell engager programs under evaluation targeting PSMA, B7-H4, and CD-19.
●The U.S. FDA cleared Abdera's Investigational New Drug (IND) application for ABD-147, and also granted it a Fast Track designation. AbCellera is a founding partner in Abdera, has a low-single-digit royalty stake in Abdera’s programs, and has a mid-single-digit equity ownership position.
●Reported the start of three additional partner-initiated programs with downstreams to reach a cumulative total of 93 partner-initiated program starts with downstreams.
●Reported the addition of one molecule in the clinic, bringing the cumulative total to 14 molecules advanced to the clinic.

1

Recent Developments
●On July 31, 2024, announced an expanded collaboration with Lilly to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience.
●On July 18, 2024, Invetx announced its upcoming acquisition by Dechra Pharmaceuticals for up to $520 million in total consideration. AbCellera is a founding partner in Invetx, has a low-single-digit royalty stake in Invetx’s programs, and has a mid-single-digit equity ownership position.

Key Business Metrics
Cumulative MetricsJune 30, 2023June 30, 2024Change %
Partner-initiated program starts with downstreams809316 %
Molecules in the clinic91456 %

AbCellera started discovery on an additional three partner-initiated programs with downstreams to reach a cumulative total of 93 partner-initiated program starts with downstreams in Q2 2024 (up from 80 on June 30, 2023). AbCellera’s partners have advanced a cumulative total of 14 molecules into the clinic (up from nine on June 30, 2023).

Discussion of Q2 2024 Financial Results
●Revenue – Total revenue was $7.3 million, compared to $10.1 million in Q2 2023. Partnerships generated research fees of $5.5 million, compared to $9.8 million in Q2 2023. Milestone payments contributed $1.5 million in the quarter.
●Research & Development (R&D) Expenses – R&D expenses were $40.9 million, compared to $36.5 million in Q2 2023, reflecting underlying continued growth in program execution, platform development, and investments in internal programs.
●Sales & Marketing (S&M) Expenses – S&M expenses were $3.1 million, compared to $3.8 million in Q2 2023.
●General & Administrative (G&A) Expenses – G&A expenses were $20.2 million, compared to $15.5 million in Q2 2023.
●Net Loss – Net loss of $36.9 million, or $(0.13) per share on a basic and diluted basis, compared to net loss of $30.5 million, or $(0.11) per share on a basic and diluted basis in Q2 2023.
●Liquidity – $697.6 million of total cash, cash equivalents, and marketable securities and with approximately $220 million in available non-dilutive government funding to execute on AbCellera's strategy, bringing total available liquidity to over $900 million.


Conference Call and Webcast
2

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics
We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. Information on changes is set forth in our Annual Report on Form 10-K for the year ended December 31, 2023.
Partner-initiated program starts with downstreams represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term.
Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached "open" status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-Looking Statements
3

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

4

AbCellera Biologics Inc.
Condensed Consolidated Statements of Loss and
Comprehensive Loss
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)
(Unaudited)

Three months ended June 30,Six months ended June 30,
2023202420232024
Revenue:
Research fees$9,830 $5,453 $20,400 $15,227 
Licensing revenue226 370 598 550 
Milestone payments– 1,500 1,250 1,500 
Total revenue10,056 7,323 22,248 17,277 
Operating expenses:
Research and development(1)
36,473 40,927 89,120 80,214 
Sales and marketing(1)
3,841 3,136 7,612 6,501 
General and administrative(1)
15,521 20,192 30,655 37,544 
Depreciation, amortization, and impairment5,610 36,522 11,124 41,366 
Total operating expenses61,445 100,777 138,511 165,625 
Loss from operations(51,389)(93,454)(116,263)(148,348)
Other (income) expense
Interest income(10,779)(9,801)(20,537)(20,202)
Grants and incentives(4,576)(3,310)(7,951)(6,585)
Other (income) expense1,970 (32,156)(1,624)(30,627)
Total other (income)(13,385)(45,267)(30,112)(57,414)
Net loss before income tax(38,004)(48,187)(86,151)(90,934)
Income tax recovery(7,476)(11,257)(15,513)(13,394)
Net loss$(30,528)$(36,930)$(70,638)$(77,540)
Foreign currency translation adjustment122 (257)(508)(353)
Comprehensive loss$(30,406)$(37,187)$(71,146)$(77,893)
Net loss per share
Basic$(0.11)$(0.13)$(0.24)$(0.26)
Diluted$(0.11)$(0.13)$(0.24)$(0.26)
Weighted-average common shares outstanding
Basic288,905,587294,217,013288,357,081293,467,753
Diluted288,905,587294,217,013288,357,081293,467,753

(1) Exclusive of depreciation, amortization, and impairment
5

AbCellera Biologics Inc.
Condensed Consolidated Balance Sheet
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
(Unaudited)
December 31, 2023June 30, 2024
Assets
Current assets:
Cash and cash equivalents$133,320 $148,312 
Marketable securities627,265 522,044 
Total cash, cash equivalents, and marketable securities760,585 670,356 
Accounts and accrued receivable30,590 36,143 
Restricted cash25,000 25,000 
Other current assets55,810 40,055 
Total current assets871,985 771,554 
Long-term assets:
Property and equipment, net287,696 318,882 
Intangible assets, net120,425 85,661 
Goodwill47,806 47,806 
Investments in equity accounted investees65,938 76,064 
Other long-term assets94,244 112,514 
Total long-term assets616,109 640,927 
Total assets$1,488,094 $1,412,481 
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other current liabilities$49,580 $43,952 
Contingent consideration payable50,475 20,027 
Deferred revenue18,958 6,401 
Total current liabilities119,013 70,380 
Long-term liabilities:
Operating lease liability71,222 66,451 
Deferred revenue8,195 7,970 
Deferred government contributions95,915 124,186 
Contingent consideration payable4,913 4,441 
Deferred tax liability30,612 21,737 
Other long-term liabilities5,906 6,348 
Total long-term liabilities216,763 231,133 
Total liabilities335,776 301,513 
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2023 and June 30, 2024: 290,824,970 and 294,665,532 shares issued and outstanding at December 31, 2023 and June 30, 2024, respectively753,199 769,966 
Additional paid-in capital121,052 140,828 
Accumulated other comprehensive loss(1,720)(2,073)
Accumulated earnings279,787 202,247 
Total shareholders' equity1,152,318 1,110,968 
Total liabilities and shareholders' equity$1,488,094 $1,412,481 
6

AbCellera Biologics Inc.
Condensed Consolidated Statement of Cash Flows
(Expressed in thousands of U.S. dollars.)
(Unaudited)
Six months ended June 30,
20232024
Cash flows from operating activities:
Net loss$(70,638)$(77,540)
Cash flows from operating activities:
Depreciation of property and equipment5,810 6,603 
Amortization and impairment of intangible assets5,314 34,763 
Amortization of operating lease right-of-use assets3,252 3,437 
Stock-based compensation31,873 35,191 
Fair value gain on contingent consideration— (30,920)
Other(4,429)(8,193)
Changes in operating assets and liabilities:
Research fees and grants receivable(24,269)(34,434)
Accrued royalties receivable9,260 — 
Income taxes payable (receivable)22,884 (5,953)
Accounts payable and accrued liabilities(2,827)(130)
Deferred revenue(4,870)(12,782)
Accrued royalties payable(16,253)— 
Deferred grant income25,566 19,757 
Other assets(4,833)(1,473)
Net cash used in operating activities(24,160)(71,674)
Cash flows from investing activities:
Purchases of property and equipment(42,185)(44,250)
Purchase of marketable securities(528,891)(426,007)
Proceeds from marketable securities422,814 539,385 
Receipt of grant funding7,693 19,750 
Long-term investments and other assets(36,757)3,950 
Investment in equity accounted investees(6,673)(10,820)
Net cash provided by (used in) investing activities(183,999)82,008 
Cash flows from financing activities:
Payment of liability for in-licensing agreement and other(863)(368)
Proceeds from long-term liabilities— 4,497 
Proceeds from exercise of stock options824 1,353 
Net cash provided by (used in) financing activities(39)5,482 
Effect of exchange rate changes on cash and cash equivalents584 (824)
Increase (decrease) in cash and cash equivalents(207,614)14,992 
Cash and cash equivalents and restricted cash, beginning of period414,651 160,610 
Cash and cash equivalents and restricted cash, end of period$207,037 $175,602 
Restricted cash included in other assets2,290 2,290 
Total cash, cash equivalents, and restricted cash shown on the balance sheet$204,747 $173,312 
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable11,718 15,944 
Right-of-use assets obtained in exchange for operating lease obligation2,945 452 
7


Inquiries
Media: Kathleen Reid: media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D., bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon, ir@abcellera.com, +1(778)729-9116
Source: AbCellera Biologics Inc.
8
C O P Y R IG H T © A B C E LL E R A Q2 2024 BUSINESS UPDATE AUGUST 6, 2024

 
C O PY R IG H T © A B C EL LE R A DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward- looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Q 2 2 0 2 4 B U S IN ES S U PD AT E

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 3 Q 2 2 0 2 4 B U S IN ES S U PD AT E We are allocating capital across 3 key priorities. Q 2 2 0 2 4 U P D A T E Engine & Capabilities Strategic Partnerships Internal Programs & Pipeline1 2 3

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 4 ABCL635 & ABCL575 are on track for clinical trial applications in Q2 2025. O U R P I P E L I N E Q 2 2 0 2 4 B U S IN ES S U PD AT E Molecule Target Indication Therapeutic Area Potential Differentiation ABCL635 undisclosed GPCR or ion channel undisclosed metabolic & endocrine conditions first in class ABCL575 OX40L atopic dermatitis immunology & inflammation best in class

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 5 We are moving four T-cell engager molecules into preclinical efficacy models. O U R E A R LY I N T E R N A L P R E C L I N I C A L P R O G R A M S Q 2 2 0 2 4 B U S IN ES S U PD AT E Target Potential Indications PSMA x CD3 prostate cancer B7-H4 x CD3 ovarian and lung cancer Undisclosed oncology CD19 x CD3 autoimmune conditions On the basis of data obtained in these studies, we may bring one or more of these programs into our development pipeline:

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 6 O U R P A R T N E R S Q 2 2 0 2 4 B U S IN ES S U PD AT E Abdera submits IND and receives FDA fast-track designation for ABD-147. ABD-147 is a radioisotope antibody conjugate for the treatment of patients with small cell lung cancer. ABD-147 is designed to deliver Actinium-225 to solid tumors expressing DLL3. AbCellera is a founding partner in Abdera and discovered the antibody from which ABD-147 is derived. AbCellera has a low-single-digit royalty stake in Abdera’s programs and a mid- single-digit equity ownership position.

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 7 O U R P A R T N E R S Q 2 2 0 2 4 B U S IN ES S U PD AT E Invetx announces upcoming acquisition by Dechra Pharmaceuticals for up to US$520M. Invetx has agreed to be acquired by Dechra, a global specialist veterinary pharmaceuticals business, for up to $520 million in total consideration. AbCellera is a founding partner in Invetx. AbCellera has a low-single-digit royalty stake in Invetx’s programs and a mid-single-digit equity ownership position.

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 8 O U R P A R T N E R S Q 2 2 0 2 4 B U S IN ES S U PD AT E We recently expanded our strategic collaboration with Lilly. multiple programs over multiple years 8 de novo programs 1 exclusive license to COVID-19 antibody program IMMUNOLOGY CARDIOVASCULAR DISEASE NEUROSCIENCE ORIG INAL COLLABORATION (2020) EXPANDED COLLABORATION

 
C O P Y R IG H T © A B C E LL E R A Q2 2024 FINANCIALS UPDATE

 
C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 10 Q 2 2 0 2 4 B U S IN ES S U PD AT E Continued progress on key business metrics and a strong cash position. in total cash, cash equivalents, & marketable securities cumulative partner- initiated program starts with downstreams internal programs advanced into IND-enabling studies ~$700M 93 2 molecules in the clinic14 In available liquidity to execute on our strategy~$920M

 
C O PY R IG H T © A B C EL LE R A 14 2 4 6 8 10 12 14 0 19 20 21 22 23 24 Q2 17162015 18 0 10 20 30 40 50 60 70 80 90 100 18 19 20 21 22 23 24 Q2 17162015 93 PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS Continuing portfolio growth. 11 FI N A N CI A LS Cumulative # of Q 2 2 0 2 4 B U S IN ES S U PD AT E MOLECULES IN THE CLINIC Cumulative # of Notable Updates on Molecule This Quarter’s Update ABD-147 New: received IND clearance and FDA fast-track designation AB-2100 Advanced into Phase 1/2 study

 
C O PY R IG H T © A B C EL LE R A Q2 2024Q2 2023 $36.5M $40.9M +$4.5M Q2 2024Q2 2023 $3.8M $3.1M -$0.7M Q2 2024Q2 2023 $15.5M $20.2M +$4.7M 12 FI N A N CI A LS RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN Operating Expenses USD Q 2 2 0 2 4 B U S IN ES S U PD AT E MILESTONES LICENSING RESEARCH FEES Revenue USD Operating expenses reflect ongoing investments, predominantly in R&D; partly offset by $7M in revenue. $1.5M $0.4M Q2 2024 $10.1M $7.3M $5.5M Q2 2023 $9.8M

 
C O PY R IG H T © A B C EL LE R A 13 FI N A N CI A LS Net loss of $37M; equivalent to ($0.13) per share (basic & diluted). NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q2 2023 Q2 2024 -$30.5M -$36.9M -$0.11 -$0.13 Q2 2023 Q2 2024 Q 2 2 0 2 4 B U S IN ES S U PD AT E Earnings USD

 
C O PY R IG H T © A B C EL LE R A 14 FI N A N CI A LS Approximately $700M in total cash, equivalents, and marketable securities. Cash Flows USD Q 2 2 0 2 4 B U S IN ES S U PD AT E INVESTING FINANCING ($31M) Other FX $522M Marketable Securities $148M Cash & Equivalents $627M Marketable Securities Jun 30, 2024 $113M Marketable Securities (net) OPERATINGDec 31, 2023 $27M* $133M Cash & Equivalents $788M ($72M) $82M $5M ($1M) $698M $27M*

 
C O PY R IG H T © A B C EL LE R A 15 THANK YOU Q 2 2 0 2 4 B U S IN ES S U PD AT E

 
v3.24.2.u1
Cover
Aug. 06, 2024
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name AbCellera Biologics Inc.
Document Period End Date Aug. 06, 2024
Entity Incorporation, State or Country Code A1
Entity File Number 001-39781
Entity Address, Postal Zip Code V5Y 0A1
Entity Central Index Key 0001703057
Amendment Flag false
Entity Address, Address Line One 2215 Yukon StreetVancouver, BC
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
City Area Code (604)
Local Phone Number 559-9005
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol ABCL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more AbCellera Biologics Charts.
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more AbCellera Biologics Charts.